Evonik buys into low-cost peptides | September 25, 2017 Issue - Vol. 95 Issue 38 | Chemical & Engineering News
Volume 95 Issue 38 | p. 13 | Concentrates
Issue Date: September 25, 2017

Evonik buys into low-cost peptides

Department: Business
Keywords: Biological chemistry, Evonik, peptide, bacteria, spin-off

Evonik Industries has acquired a minority stake in Numaferm, a spin-off from Heinrich Heine University that is developing a process for making peptides using bacteria. Evonik is one of a handful of companies, including venture capital firms, that have invested a combined total of about $1.2 million in the spin-off. Numaferm claims it can make peptides at 1/1,000th of the price of standard chemical process costs (about $1.2 million per kg). Numaferm’s technology is cheaper partly because to make 1 kg of peptide, it uses 1 metric ton of raw materials compared with 25 metric tons for chemical processes, the firm says.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment